Lamivudine/tenofovir
Lamivudine/tenofovir disoproxil, sold under the brand name Cimduo among others, is a fixed-dose combination antiretroviral medication for the treatment of HIV/AIDS in adults and children weighing more than 35 kilograms (77 lb). It contains lamivudine and tenofovir disoproxil. It is taken by mouth.
| Combination of | |
|---|---|
| Lamivudine | Nucleoside reverse transcriptase inhibitor |
| Tenofovir disoproxil | Nucleotide reverse transcriptase inhibitor |
| Clinical data | |
| Trade names | Cimduo, Temixys |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a618039 |
| License data | |
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| KEGG | |
Lamivudine/tenofovir was approved for medical use in the United States in February 2018.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.